Increase in awareness regarding the non-compliance of drug therapy is expected to drive the demand for United States connected drug delivery devices market for the forecast period.
According to TechSci Research report, “United States Connected Drug Delivery Devices Market By Product Type (Connected Sensors v/s Integrated Connected Devices) By Technology (Bluetooth, Near Field Communication, Others) By Application (Asthma & COPD, Diabetes, Others) By End User (Healthcare Providers v/s Homecare) By Region, Company Forecast & Opportunities, 2026”, The United States connected drug delivery devices market is expected to witness significant growth for the next five years. Connected drug delivery devices aids to maintain proper administration of drugs with ensuring no errors without the assistance of healthcare professionals. Connected drug delivery devices are quick, patient-focused, user-friendly, and easily accessible. These devices basically designed to support multifunctional tasks along with support the patient superior supervision and counselling activity. It consists of features such as reminders, adherence trackers, patient diaries which collectively store all the patient information. Increasing occurrence of chronic diseases such as diabetes, asthma and COPD is contributing to surge the demand for connected drug delivery devices. Rise in demand for connected drug delivery services by healthcare sector and home-care settings is expected to boost the connected drug delivery devices product demand. Adoption of latest technology is making connected drug delivery devices capable of drug identification and delivery.
The COVID-19 outbreak across the world which has been declared as pandemic by World Health Organization has affected several countries adversely. Leading authorities in United States imposed lockdown restrictions and released a set of precautionary measures to contain the spread of novel coronavirus. Coronavirus affected patients started suffering from shortness of breath along with coughing and sneezing. United States authorities increased the capacity of hospitals as a greater number of patients were getting affected daily and getting admitted into the hospital facilities. Self-administration of drug delivery was promoted to provide proper treatment to patients which boosted the connected drug delivery devices demand.
Browse XX Figures spread through XX Pages and an in-depth TOC on “United States Connected Drug Delivery Devices Market”.
United States connected drug delivery devices market is segmented into product type, technology, application, end user, regional distribution, and company. Based on end user, market can be divided into healthcare providers and homecare. The healthcare providers end user segment is expected to dominate the market for the forecast period, 2022-2026. Increasing prevalence of chronic diseases along with cardiovascular diseases, diabetes and chronic obstructive pulmonary diseases are some of the critical diseases requiring proper treatment and follow up of prescribed medicines. Use of connected drug delivery services is beneficial in disease treatment as it maintains the health record of patients. It also monitors the drug usage and ensure timely drug delivery; therefore, it is in high demand from healthcare sector. Based on technology, market can be fragmented into Bluetooth, near field communication, and others. The Bluetooth technology segment is expected to account for major market share for the next five years as it affordable and easily available than its other available counterparts. Bluetooth technology is in high demand as it can assist in easy connection between connected drug delivery device and smartphone. High usage and technological advancements of the technology is expected to foster the demand for connected drug delivery devices market.
Abbott Laboratories, Inc., F. Hoffmann-La Roche Ltd. (USA), Teva USA, Merck & Co., West Pharmaceutical Services, Inc., Molex LLC (Phillips Medisize), Cohero Health, Inc., Becton, Dickinson, and Company, Unilife Corporation are the leading players operating in United States connected drug delivery devices market. Manufacturers are increasingly focusing on research and development process to fuel higher growth in the market. To meet evolving customer demand with respect to better efficiency and durability, several connected drug delivery devices manufacturers are coming up with their technologically advanced offerings.
Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7593
Customers can also request for 10% free customization on this report.
“High-end investments by the major players for research and development activities coupled with inclusion of emerging technologies such as big data analytics, artificial intelligence to upgrade the existing infrastructure of connected drug delivery devices is expected to carte lucrative opportunities for the market growth. Launch of novel products promoting maximum patient engagement and connectivity along with rise in geriatric population in United States who require the external assistance for drug consumption is expected to propel the connected drug delivery devices market growth till 2026” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.
“United States Connected Drug Delivery Devices Market By Product Type (Connected Sensors v/s Integrated Connected Devices) By Technology (Bluetooth, Near Field Communication, Others) By Application (Asthma & COPD, Diabetes, Others) By End User (Healthcare Providers v/s Homecare) By Region, Company Forecast & Opportunities, 2026” has evaluated the future growth potential of United States connected drug delivery devices market and provided statistics & information on market size, shares, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in the of United States connected drug delivery devices market.
Mr. Ken Mathews
708 Third Avenue,
New York – 10017